Kisspeptin for infertility treatment - research and protocols

# Kisspeptin for Infertility Treatment: Research and Protocols

Infertility, defined as the inability to conceive after 12 months of regular unprotected intercourse, affects millions of couples worldwide. While various factors contribute to infertility, disruptions in the intricate hormonal cascade regulating reproduction are often at its core. Among the emerging therapeutic targets, kisspeptin, a neuropeptide produced in the hypothalamus, has garnered significant attention for its pivotal role in initiating and maintaining reproductive function. This article delves into the current research and potential protocols for utilizing kisspeptin in the treatment of infertility.

Understanding Kisspeptin's Role in Reproduction

Kisspeptin, encoded by the KISS1 gene, is a crucial upstream regulator of the hypothalamic-pituitary-gonadal (HPG) axis, the central hormonal pathway controlling reproduction. It acts primarily by stimulating gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. GnRH, in turn, triggers the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which are essential for gamete development and steroid hormone production in the gonads [1].

Key functions of kisspeptin in reproduction include:

Puberty initiation: Kisspeptin signaling is a critical trigger for the onset of puberty.

Ovulation: In females, kisspeptin plays a vital role in the preovulatory GnRH surge, which is necessary for ovulation.

Spermatogenesis: In males, kisspeptin contributes to the pulsatile release of GnRH, which is essential for maintaining spermatogenesis.

Feedback regulation: Kisspeptin neurons are sensitive to sex steroid hormones (estrogen and testosterone), providing a feedback mechanism to regulate GnRH release.

Disruptions in kisspeptin signaling can lead to various reproductive disorders, including hypogonadotropic hypogonadism (HH), a condition characterized by low levels of GnRH, LH, and FSH, resulting in impaired gonadal function and infertility.

Kisspeptin in Female Infertility

The application of kisspeptin in female infertility primarily focuses on conditions where the GnRH surge is absent or insufficient, such as hypothalamic amenorrhea (HA) and in controlled ovarian stimulation (COS) protocols.

Hypothalamic Amenorrhea (HA)

HA is a common cause of infertility characterized by an absence of menstruation due to impaired GnRH pulsatility, often triggered by stress, excessive exercise, or inadequate nutrition. Traditional treatments involve lifestyle modifications or pulsatile GnRH therapy.

Research and Protocols:

Restoring GnRH pulsatility: Studies have shown that exogenous administration of kisspeptin can stimulate GnRH and subsequent LH/FSH release in women with HA [2].

Ovulation induction: Repeated kisspeptin administration has been demonstrated to induce ovulation in some women with HA, suggesting its potential as a therapeutic agent [3].

Dosing considerations: Research protocols have explored various dosing regimens. For example, intravenous (IV) infusions of kisspeptin-54 (the most potent form) at doses ranging from 0.1 to 10 µg/kg have been used to assess LH pulsatility. For ovulation induction, more prolonged or repeated subcutaneous (SC) administrations might be considered. However, standardized protocols for long-term use in HA are still under investigation.

Kisspeptin as an ovulatory trigger: Kisspeptin has emerged as a promising alternative to hCG or GnRH agonists for triggering ovulation in COS. By directly stimulating endogenous GnRH release, kisspeptin can induce an LH surge that mimics the natural physiological process, potentially reducing the risk of OHSS [4].

Reduced OHSS risk: Studies have shown that kisspeptin-triggered cycles result in a lower incidence of moderate to severe OHSS compared to hCG triggers, without compromising oocyte yield or pregnancy rates [5]. This is attributed to the shorter half-life of endogenous LH compared to hCG, leading to less sustained ovarian stimulation post-trigger.

Dosing for trigger: Typical protocols for ovulatory triggering in COS involve a single subcutaneous (SC) injection of kisspeptin-54, often in the range of 0.8 to 1.6 nmol/kg (approximately 5-10 mg for an average adult). The optimal timing and dose are still being refined, but it is generally administered when follicles reach appropriate size, similar to hCG or GnRH agonist triggers.

Summary Table: Kisspeptin in Female Infertility

| Condition | Mechanism of Action | Potential Benefits | Current Status & Considerations